Meibomian Gland Dysfunction and Dry Eye Diseases
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Ophthalmology".
Deadline for manuscript submissions: 25 March 2026 | Viewed by 8
Special Issue Editors
2. Lid and Meibomian Gland Working Group, Saitama 3370042, Japan
Interests: dry eye; meibomian glands; ocular surface; meibomian gland dysfunction
Special Issues, Collections and Topics in MDPI journals
Interests: dry eye; meibomian gland; meibomian gland dysfunction; interferometry
Special Issue Information
Dear Colleagues,
Meibomian gland dysfunction (MGD) is a leading cause of evaporative dry eye disease and remains a key area of research and clinical interest in the field of ocular surface diseases. Advances in diagnostic imaging, such as non-contact meibography and lipid layer analysis, have enabled the more precise evaluation of meibomian gland structure and function. Moreover, recent progress in understanding the pathophysiology of MGD, including the roles of inflammation, microbial flora, and systemic factors, has contributed to the development of novel therapeutic strategies. This Special Issue invites original research articles, reviews, and clinical studies focusing on all aspects of meibomian gland dysfunction and dry eye disease, including epidemiology, diagnosis, underlying mechanisms, innovative treatment modalities, and emerging technologies. We welcome submissions that aim to improve the understanding, diagnosis, and management of MGD and dry eye disease, ultimately enhancing patient outcomes.
Dr. Reiko Arita
Prof. Dr. KyoungYul Seo
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- meibomian gland
- meibomian gland dysfunction
- dry eye disease
- ocular surface
- meibography
- lipid layer
- tear film
- inflammation
- therapy
- diagnosis
- epidemiology
- clinical study
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
